Home LiteratureArticle Details
PMID: 18959599 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association ·Vol. 25 ·No. 8 ·2008-08-00 ·Pages 889-94

Gribble FM

Abstract

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal hormones that play an important role in stimulating postprandial insulin release from pancreatic beta-cells. Agents that either mimic GLP-1 or prevent its degradation are now available for the treatment of Type 2 diabetes, and strategies to enhance endogenous GLP-1 release are under assessment. As intestinal peptides have a range of actions, including appetite regulation and coordination of fat metabolism, harnessing the enteric endocrine system is a promising new field for drug development.

MeSH Terms
Diabetes Mellitus, Type 2/drug therapy,metabolism Gastric Inhibitory Polypeptide/metabolism,therapeutic use Glucagon-Like Peptide 1/metabolism,therapeutic use Humans Incretins/metabolism Insulin/metabolism Insulin-Secreting Cells/metabolism
Chemicals
Incretins Insulin Gastric Inhibitory Polypeptide Glucagon-Like Peptide 1
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Gribble F M
Cambridge Institute for Medical Research and Department of Clinical Biochemistry, Wellcome Trust/MRC Building, Addenbrooke's Hospital, Cambridge, UK. fmg23@cam.ac.uk
References (26)
26 references, click to expand
  1. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line.
    Diabetes. 2003 May;52(5):1147-54 PMID: 12716745
  2. Glucose-sensing in glucagon-like peptide-1-secreting cells.
    Diabetes. 2002 Sep;51(9):2757-63 PMID: 12196469
  3. Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons.
    Am J Physiol Regul Integr Comp Physiol. 2003 Aug;285(2):R470-8 PMID: 12714357
  4. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system.
    Endocrinology. 2004 Jun;145(6):2653-9 PMID: 15044356
  5. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
    Diabetologia. 1986 Jan;29(1):46-52 PMID: 3514343
  6. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
    Diabetologia. 1993 Aug;36(8):741-4 PMID: 8405741
  7. Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line.
    Mol Endocrinol. 1994 Dec;8(12):1646-55 PMID: 7535893
  8. Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum.
    Acta Diabetol. 1997 Mar;34(1):18-21 PMID: 9134052
  9. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.
    Pflugers Arch. 1998 Apr;435(5):583-94 PMID: 9479010
  10. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.
    J Comp Neurol. 1999 Jan 11;403(2):261-80 PMID: 9886047
  11. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells.
    Diabetologia. 2004 Sep;47(9):1592-601 PMID: 15365617
  12. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells.
    Horm Metab Res. 2004 Nov-Dec;36(11-12):787-94 PMID: 15655710
  13. The [pre-] history of the incretin concept.
    Regul Pept. 2005 Jun 15;128(2):87-91 PMID: 15780427
  14. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Lancet. 2006 Nov 11;368(9548):1696-705 PMID: 17098089
  15. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice.
    Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):943-8 PMID: 17213311
  16. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1.
    Diabetes. 2007 Feb;56(2):438-43 PMID: 17259389
  17. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.
    Endocr Rev. 2007 Feb;28(1):84-116 PMID: 17261637
  18. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes.
    Diabetes. 2007 Jun;56(6):1551-8 PMID: 17360984
  19. Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line.
    Diabetologia. 2007 Oct;50(10):2181-9 PMID: 17643200
  20. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.
    Endocrinology. 2007 Oct;148(10):4965-73 PMID: 17584962
  21. The physiology of glucagon-like peptide 1.
    Physiol Rev. 2007 Oct;87(4):1409-39 PMID: 17928588
  22. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release.
    Obesity (Silver Spring). 2008 Feb;16(2):298-305 PMID: 18239636
  23. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Endocrinology. 2008 May;149(5):2038-47 PMID: 18202141
  24. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
    Diabetes. 2008 May;57(5):1340-8 PMID: 18162504
  25. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.
    Lancet. 2002 Mar 9;359(9309):824-30 PMID: 11897280
  26. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13 PMID: 12788877
Article Info
Journal
Diabetic medicine : a journal of the British Diabetic Association
Abbr.
Diabet Med
ISSN
1464-5491
DOI
10.1111/j.1464-5491.2008.02514.x
Email
fmg23@cam.ac.uk
Published
2008-08-00
Pages
889-94
Language
English
Region
England
NLM ID
8500858
PMCID
PMC2613238
Subset
IM
Grants
Wellcome Trust · 071187 · United Kingdom
External Links
PubMed source DOI: 10.1111/j.1464-5491.2008.02514.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2